Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Larotrectinib in NTRK Amplification Positive Solid Tumors
NCT04879121Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2021
- Primary completion
- Nov 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of larotrectinib in solid tumor, sponsored by University of Texas MD Anderson Cancer Center. Started Apr 2021; status: recruiting.
02
Drugs
larotrectinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04879121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04879121.